Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition

Behavioural Pharmacology

Volumn 20, Issue 1, 2009, Pages 56-66

  Schlumberger, Chantal ^a   Schäfer, Daniela ^a   Barberi, Caroline ^a   Morè, Lorenzo ^a   Nagel, Jens ^a   Pietraszek, Matgorzata ^a   Schmidt, Werner J ^b   Danysz, Wojciech ^a  

^a MERZ PHARMACEUTICALS GMBH   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Elevated plus maze; Hyperiocomotion; LY354740; Passive avoidance; Phencyclidine; Rat; Schizophrenia; Spontaneous alternation behaviour

Indexed keywords

EGLUMETAD; PHENCYCLIDINE; AMINO ACID RECEPTOR STIMULATING AGENT; ANXIOLYTIC AGENT; BICYCLO COMPOUND; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; LOCOMOTION; MALE; MAZE TEST; NONHUMAN; POSITIVE SYNDROME; RAT; TRANQUILIZING ACTIVITY; WORKING MEMORY; ANIMAL; ANIMAL BEHAVIOR; AVOIDANCE BEHAVIOR; DISEASE MODEL; DRUG POTENTIATION; DRUG SCREENING; EXPLORATORY BEHAVIOR; MOTOR ACTIVITY; PSYCHOLOGY; SCHIZOPHRENIA; SPRAGUE DAWLEY RAT; STARTLE REFLEX;

ANIMALS; ANTI-ANXIETY AGENTS; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; BICYCLO COMPOUNDS; COGNITION; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; EXCITATORY AMINO ACID AGONISTS; EXPLORATORY BEHAVIOR; MALE; MAZE LEARNING; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; STARTLE REACTION;

EID: 61449150536     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e3283242f57     Document Type: Article

References (52)

1. Abe S, Suzuki T, Ito T, Yamaguchi M, Baba A, Hori T, et al. (2001). Effects of single and repeated phencyclidine administration on the expression of metabotropic glutamate receptor subtype mRNAs in rat brain. Neuropsycho- pharmacology 25:173-184.
2. Abekawa T, Honda M, Ito K, Koyama T (2003). Effects of NRA0045, a novel potent antagonist at dopamine 04, 5-HT2A and alpha 1 adrenaline receptors, and NRA0160, a selective D4 receptor antagonist, on phencyclidine- induced behavior and glutamate release in rats. Psychopharmacology (Berl) 169:247-256.
3. Adams B, Moghaddam B (1998). Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J Neurosci 18:5545-5554.
4. Adams BW, Moghaddam B (2001). Effect of clozapine, haloperidol, or M100907 on phencyclidine-activated glutamate efflux in the prefrontal cortex. Biol Psychiatry 50:750-757.
5. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ (1999). Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686-1696.
6. American Psychiatric Association (1994). Diagnostic and statistical manual of mental disorders: DSM-IV. 4th ed. Washington, DC: American Psychiatric Press.
7. Anderman B, Griffith RW (1977). Clozapine-induced agranulocytosis: a situation report up to August 1976. Eur J Clin Pharmacol 11:199-201.
8. Andlin-Sobocki P, Rossler W (2005). Cost of psychotic disorders in Europe. Eur J Neurol 12 (Suppl 1):74-77.
9. Anis NA, Berry SC, Burton NR, Lodge D (1983). The dissociative anaesthetics ketamine and phencyclidine, selectively inhibit excitation of central mammalian neurons by N-methylaspartate. Br J Pharmacol 79:565-575.
10. Aultman JM, Moghaddam B (2001). Distinct contributions of glutamate and dopamine receptors to temporal aspects of rodent working memory using a clinically relevant task Psychopharmacology (Berl) 153:353-364.
11. Battaglia G, Monn JA, Schoepp DD (1997). In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats. Neurosci Lett 229: 161-164.
12. Borison RL, Pathiraja AP, Diamond Bl, Meibach RC (1992). Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 28: 213-218.
13. Cartmell J, Monn JA, Schoepp DD (1999). The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus D-amphetamine motor behaviors in rats. J Pharmacol Exp Ther 291:161 -170.
14. Conn PJ, Pin JP (1997). Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37:205-237.
15. Drejer J, Honore T (1987). Phencyclidine analogues inhibit NMDA-stimulated [3H]GABA release from cultured cortex neurons. Eur J Pharmacol 143: 287-290.
16. Fell MJ, Johnson BG, Svensson KA, Schoepp DD (2008). Evidence for the role of mGlu2 not mGlu3 receptors in the pre-clinical antipsychotic pharmacology of the mGlu2/3 receptor agonist LY404039. J Pharmacol Exp Ther 326:209-217.
17. Ferris P, Seward E, Dawson GR (2001). Interactions between LY354740, a group II metabotropic agonist and the GABA(A)-benzodiazepine receptor complex in the rat elevated plus-maze. J Psychopharmacol 15:76-82.
18. Finnegan KT, Kanner Ml, Meltzer HY (1976). Phencyclidine-induced rotational behavior in rats with nigrostriatal lesions and its modulation by dopaminergic and cholinergic agents. Pharmacol Biochem Behav 5:651 -660.
19. Harich S, Gross G, Bespalov A (2007). Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment. Psychopharmacology (Berl) 192:511-519.
20. Harrison P, Lyon L, Sartorius LJ, Burnet P, Lane T (2008). The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia. J Psychopharmacol 22:308-322.
21. Heinrichs RW (2005). The primacy of cognition in schizophrenia. Am Psychol 60:229-242.
22. Helton DR, Tizzano JP, Monn JA, Schoepp DD, Kallman MJ (1998). Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J Pharmacol Exp Ther 284:651-660.
23. Henry SA, Lehmann-Masten V, Gasparini F, Geyer MA, Markou A (2002). The mGluR5 antagonist MPER but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity. Neuropharmacology 43:1199-1209.
24. Higgins GA, Ballard TM, Kew JN, Richards JG, Kemp JA, Adam G, et al. (2004). Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent. Neuropharmacology 46:907-917.
25. Horacek J, Bubenikova-Valesova V, Kopecek M, Palenioek T, Dockery C, Mohr P, Hoschl C (2006). Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 20:389-409.
26. Imre G, Fokkema DS, Ter Horst GJ (2006a). Subchronic administration of LY354740 does not modify ketamine-evoked behavior and neuronal activity in rats. Eur J Pharmacol 544:77-81.
27. Imre G, Salomons A, Jongsma M, Fokkema DS, Den Boer JA, Ter Horst GJ (2006b). Effects of the mGluR2/3 agonist LY379268 on ketamine-evoked behaviours and neurochemical changes in the dentate gyrus of the rat. Pharmacol Biochem Behav 84:392-399.
28. Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301 -1308.
29. Johnson MP, Baez M, Jagdmann GE Jr, Britton TC, Large TH, Callagaro DO, et al. (2003). Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of /V-(4-(2- methoxyphenoxy)-phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine. J Med Chem 46:3189-3192.
30. Koek W, Woods JH, Wnger GD (1988). MK-801, a proposed noncompetitive antagonist of excitatory amino acid neurotransmission, produces phencyclidine-like behavioral effects in pigeons, rats and rhesus monkeys. J Pharmacol Exp Ther 245:969-974.
31. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, et al. (2003). H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28:519-526.
32. Krystal JH, Abi-Saab W, Perry E, D'Souza DC, Liu N, Gueorguieva R, et al. (2005). Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl) 179:303-309.
33. Lorrain DS, Baccei CS, Bristow LJ, Anderson JJ, Varney MA (2003a). Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 117:697-706.
34. Lorrain DS, Schaffhauser H, Campbell UC, Baccei CS, Correa LD, Rowe B, et al. (2003b). Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge. Neuropsychopharmacology 28:1622-1632.
35. Luby ED, Cohen RC, Rosenbaum B, Gottlieb JS, Kelly R (1959). Study of a new schizophrenomimetic drug: Sernyl. Arch Neurol Psychiatry 81: 363-369.
36. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al. (2006). Effectiveness of clozapine versus olanzapine, quetiapine and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163:600-610.
37. Mclntyre RS, McCann SM, Kennedy SH (2001). Antipsychotic metabolic effects: weight gain, diabetes mellitus and lipid abnormalities. Can J Psychiatry 46:273-281.
38. Moghaddam B, Adams BW (1998). Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281: 1349-1352.
39. Monn JA, Valli MJ, Massey SM, Wright RA, Salhoff CR, Johnson BG, et al. (1997). Design, synthesis, and pharmacological characterization of (+)-2-aminobi- cyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J Med Chem 40:528-537.
40. Moore NA, Rees G, Monn JA (1999). Effects of the group II metabotropic glutamate receptor agonist, LY354740 on schedule-controlled behaviour in rats. Behav Pharmacol 10:319-325.
41. Ossowska K, Pietraszek M, Wardas J, Nowak G, Zajaczkowski W, Woffarth S, Pile A (2000). The role of glutamate receptors in antipsychotic drug action. Amino Acids 19:87-94.
42. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, et al. (2007). Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 13:1102-1107.
43. Pilc A (2003). LY-354740 (Eli Lilly). IDrugs 6:66-71.
44. Reichenberg A, Weiser M, Caspi A, Knobler HY, Lubin G, Harvey PD, et al. (2006). Premorbid intellectual functioning and risk of schizophrenia and spectrum disorders. J Clin Exp Neuropsychol 28:193-207.
45. Rorick-Kehn LM, Johnson BG, Knitowski KM, Salhoff CR, Witkin JM, Perry KW, et al. (2007). In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology (Berl) 193:121-136.
46. Schreiber R, Lowe D, Voerste A, DeVry J (2000). LY354740 affects startle responding but not sensorimotor gating or discriminative effects of phencyclidine. Eur J Pharmacol 388:R3-R4.
47. Spinelli S, Ballard T, Gatti-McArthur S, Richards GJ, Kapps M, Woltering T, et al. (2005). Effects of the mGluR2/3 agonist LY354740 on computerized tasks of attention and working memory in marmoset monkeys. Psychopharmacology (Berl) 179:292-302.
48. Spooren WP, Gasparini F, Van der Putten H, Koller M, Nakanishi S, Kuhn R (2000). Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice. Eur J Pharmacol 397:R1 -R2.
49. Spooren W, Ballard T, Gasparini F, Amalric M, Mutel V, Schreiber R (2003). Insight into the function of group I and group II metabotropic glutamate (mGlu) receptors: behavioural characterization and implications for the treatment of CNS disorders. Behav Pharmacol 14:257-277.
50. Tizzano JR Griffey Kl, Schoepp DD (2002). The anxiolytic action of mGlu2/3 receptor agonist, LY354740, in the fear-potentiated startle model in rats is mechanistically distinct from diazepam. Pharmacol Biochem Behav 73:367-374.
51. Weiden Rl (2007). EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract 13:13-24.
52. Woolley ML, Pemberton DJ, Bate S, Corti C, Jones DN (2008). The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology (Berl) 196:431-440.